XML 25 R15.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Prepaids and Other Current Assets (Notes) | 6 Months Ended
--- | ---
Jun. 30, 2018
Prepaid Expense and Other Assets, Current [Abstract] |
Other Current Assets [Text Block] | Prepaid expenses and other current assets consist of the following (in thousands):
|  | June 30, 2018 |  | December 31, 2017
Deposits |  | $ | 431 |  |  | $ | 21,940 |
Other prepaid expenses and receivables |  | 13,897 |  |  | 4,208 |
Prepaid insurance and property taxes |  | 2,045 |  |  | 2,580 |
VAT/GST receivable |  | 5,577 |  |  | 8,097 |
Deferred tax charge |  | 1,912 |  |  | 1,326 |
Other |  | 4,880 |  |  | 3,135 |
|  | $ | 28,742 |  |  | $ | 41,286 |
Related-party receivables consist of the following (in thousands):
|  | June 30, 2018 |  | December 31, 2017
Third-party receivables due from Pfizer |  | $ | 66,651 |  |  | $ | 36,425 |
HIS business acquisition related |  | 11,707 |  |  | 62,382 |
|  | $ | 78,358 |  |  | $ | 98,807 |
Third-party receivables due from Pfizer relates to trade accounts receivable that has already been collected from customers by Pfizer on our behalf. HIS business acquisition related receivables include amounts due from Pfizer related to the manufacturing and supply agreements and amounts we prepaid to Pfizer for operational expenses under the transition services agreement. Pfizer became a related party to us when we issued 3.2 million shares of our common stock as partial consideration for the acquisition of HIS. On February 3, 2017, we entered into a transitional services agreement and two Manufacturing and Supply Agreements ("MSAs") with Pfizer (see Note 19, Collaborative and Other Arrangements). During the three and six months ended June 30, 2018, the revenue for goods manufactured for Pfizer was $19.5 million and $37.6 million, respectively. During the three and six months ended June 30, 2017, the revenue for goods manufactured for Pfizer was $21.0 million and $35.7 million, respectively. For the three and six months ended June 30, 2018, the cost of product manufactured by Pfizer for us was $22.6 million and $39.8 million, respectively. For the three and six months ended June 30, 2017, the cost of product manufactured by Pfizer for us was $26.3 million and $38.8 million, respectively.

X
- Definition The entire disclosure for other current assets. + References No definition available. + Details
Name: | us-gaap_OtherCurrentAssetsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration